NASDAQ · Biotechnology

Mural Oncology plc (MURA) Stock

$2.04 +0.00% NASDAQ: MURA Healthcare

Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer.

Valuation

MetricValue
Price$2.04
Market Cap$35.38M
P/E Ratio-0.41
P/B Ratio0.64
P/S Ratio0.00
EPS (TTM)$-7.58
52-Week High$4.74
52-Week Low$0.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-114.70%
ROA-129.00%
ROCE-126.21%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.06
Current Ratio5.90

Annual Financials (USD)

Metric2021202220232024
Revenue$0$0$0$0
Operating Profit$-175.0M$-185.0M$-195.0M$-138.0M
Net Profit$-175.0M$-190.0M$-207.0M$-129.0M
EPS$-10.51$-11.37$-12.43$-7.58
Op Margin————

Balance Sheet (USD)

Metric2021202220232024
Total Assets$35.0M$34.0M$302.0M$169.0M
Total Liabilities$53.0M$55.0M$38.0M$29.0M
Cash$0$0$271.0M$115.0M
Borrowings$25.0M$19.0M$15.0M$8.0M

Latest News

UK trade bodies call on Wales to change DRS plans Just Drinks · Jul 16, 2026 S&P 500, Nasdaq fall as chip stocks weaken; earnings and data in focus Reuters · Jul 16, 2026 Hexaware and Factory Partner to Bring Agent-native Development to Global Enterprises PR Newswire · Jul 16, 2026 LAUGH FACTORY COMEDY CAMP'S 40th ANNIVERSARY GRADUATION ON JULY 18TH ALSO SPOTLIGHTS TIFFANY HADDISH PR Newswire · Jul 16, 2026 Net Asset Value(s) Business Wire · Jul 16, 2026

Cash Flow (USD)

Metric2021202220232024
Operating Cash Flow$-157.0M$-169.0M$-194.0M$-129.0M
Investing Cash Flow$-9.0M$-11.0M$-7.0M$-25.0M
Financing Cash Flow$161.0M$174.0M$469.0M$0
Net Cash Flow$0$0$271.0M$-154.0M
Free Cash Flow$-161.0M$-174.0M$-198.0M$-129.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA0.24
FCF Yield-244.91%
Quick Ratio5.90
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATHEAlterity Therapeutics Limited $4.70 -5.62% -6.89 $42.60M 0.00%
BCABBioAtla, Inc. $3.40 +0.89% -0.08 $4.29M 0.00%
BTAIBioXcel Therapeutics, Inc. $0.87 +2.30% -0.13 $26.77M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About Mural Oncology plc

Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.

Mural Oncology plc is headquartered in IE.

Mural Oncology plc (MURA) stock trades at $2.04 with a market capitalization of $35.38M. The stock is valued at a price-to-earnings (P/E) ratio of -0.41, price-to-book of 0.64, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.95 and $4.74, and currently trades 57.0% below its 52-week high.

On profitability, Mural Oncology plc generates a return on equity (ROE) of -114.70%, return on capital employed of -126.21%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.muraloncology.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides